Radiotherapy after prostatectomy

Giuseppe Sanguineti, Paola Franzone, Laura Culp, Michela Marcenaro, Salvina Barra, Vito Vitale

Research output: Contribution to journalArticle

Abstract

Aims and background: The role of radiotherapy after prostatectomy is controversial. This paper tries to give some guidelines for everyday practice through an analysis of literature data. Methods: The potential role of radiotherapy in the adjuvant and salvage setting is discussed. We also report and interpret available literature data for both settings. Results: As regards an increase in or detectable prostate-specific antigen (PSA) after radical prostatectomy, about 40-50% of patients are rendered bNED with local salvage radiotherapy, but only 10-50% are long-term (5 years) biochemically controlled. A timely salvage treatment is crucial to optimize control probability. As regards adjuvant radiotherapy for undetectable postoperative PSA in patients at high risk of failure as judged on pathology, results are more encouraging. Recent data report bNED rates ≥70% at 5 years. Conclusions: Although results are far from satisfactory, salvage radiotherapy should be considered for every patient with an increased or detectable PSA after surgery. Adjuvant radiotherapy seems preferable to salvage radiotherapy for patients at high (>30%) risk of failure.

Original languageEnglish
Pages (from-to)445-452
Number of pages8
JournalTumori
Volume88
Issue number6
Publication statusPublished - Nov 2002

Fingerprint

Prostatectomy
Adjuvant Radiotherapy
Radiotherapy
Prostate-Specific Antigen
Salvage Therapy
Practice Guidelines
Pathology

Keywords

  • Adjuvant radiotherapy
  • Prostate carcinoma
  • Prostatectomy
  • Salvage radiotherapy

ASJC Scopus subject areas

  • Cancer Research

Cite this

Sanguineti, G., Franzone, P., Culp, L., Marcenaro, M., Barra, S., & Vitale, V. (2002). Radiotherapy after prostatectomy. Tumori, 88(6), 445-452.

Radiotherapy after prostatectomy. / Sanguineti, Giuseppe; Franzone, Paola; Culp, Laura; Marcenaro, Michela; Barra, Salvina; Vitale, Vito.

In: Tumori, Vol. 88, No. 6, 11.2002, p. 445-452.

Research output: Contribution to journalArticle

Sanguineti, G, Franzone, P, Culp, L, Marcenaro, M, Barra, S & Vitale, V 2002, 'Radiotherapy after prostatectomy', Tumori, vol. 88, no. 6, pp. 445-452.
Sanguineti G, Franzone P, Culp L, Marcenaro M, Barra S, Vitale V. Radiotherapy after prostatectomy. Tumori. 2002 Nov;88(6):445-452.
Sanguineti, Giuseppe ; Franzone, Paola ; Culp, Laura ; Marcenaro, Michela ; Barra, Salvina ; Vitale, Vito. / Radiotherapy after prostatectomy. In: Tumori. 2002 ; Vol. 88, No. 6. pp. 445-452.
@article{384d32e02e83428f8eda605a940fcbcc,
title = "Radiotherapy after prostatectomy",
abstract = "Aims and background: The role of radiotherapy after prostatectomy is controversial. This paper tries to give some guidelines for everyday practice through an analysis of literature data. Methods: The potential role of radiotherapy in the adjuvant and salvage setting is discussed. We also report and interpret available literature data for both settings. Results: As regards an increase in or detectable prostate-specific antigen (PSA) after radical prostatectomy, about 40-50{\%} of patients are rendered bNED with local salvage radiotherapy, but only 10-50{\%} are long-term (5 years) biochemically controlled. A timely salvage treatment is crucial to optimize control probability. As regards adjuvant radiotherapy for undetectable postoperative PSA in patients at high risk of failure as judged on pathology, results are more encouraging. Recent data report bNED rates ≥70{\%} at 5 years. Conclusions: Although results are far from satisfactory, salvage radiotherapy should be considered for every patient with an increased or detectable PSA after surgery. Adjuvant radiotherapy seems preferable to salvage radiotherapy for patients at high (>30{\%}) risk of failure.",
keywords = "Adjuvant radiotherapy, Prostate carcinoma, Prostatectomy, Salvage radiotherapy",
author = "Giuseppe Sanguineti and Paola Franzone and Laura Culp and Michela Marcenaro and Salvina Barra and Vito Vitale",
year = "2002",
month = "11",
language = "English",
volume = "88",
pages = "445--452",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Radiotherapy after prostatectomy

AU - Sanguineti, Giuseppe

AU - Franzone, Paola

AU - Culp, Laura

AU - Marcenaro, Michela

AU - Barra, Salvina

AU - Vitale, Vito

PY - 2002/11

Y1 - 2002/11

N2 - Aims and background: The role of radiotherapy after prostatectomy is controversial. This paper tries to give some guidelines for everyday practice through an analysis of literature data. Methods: The potential role of radiotherapy in the adjuvant and salvage setting is discussed. We also report and interpret available literature data for both settings. Results: As regards an increase in or detectable prostate-specific antigen (PSA) after radical prostatectomy, about 40-50% of patients are rendered bNED with local salvage radiotherapy, but only 10-50% are long-term (5 years) biochemically controlled. A timely salvage treatment is crucial to optimize control probability. As regards adjuvant radiotherapy for undetectable postoperative PSA in patients at high risk of failure as judged on pathology, results are more encouraging. Recent data report bNED rates ≥70% at 5 years. Conclusions: Although results are far from satisfactory, salvage radiotherapy should be considered for every patient with an increased or detectable PSA after surgery. Adjuvant radiotherapy seems preferable to salvage radiotherapy for patients at high (>30%) risk of failure.

AB - Aims and background: The role of radiotherapy after prostatectomy is controversial. This paper tries to give some guidelines for everyday practice through an analysis of literature data. Methods: The potential role of radiotherapy in the adjuvant and salvage setting is discussed. We also report and interpret available literature data for both settings. Results: As regards an increase in or detectable prostate-specific antigen (PSA) after radical prostatectomy, about 40-50% of patients are rendered bNED with local salvage radiotherapy, but only 10-50% are long-term (5 years) biochemically controlled. A timely salvage treatment is crucial to optimize control probability. As regards adjuvant radiotherapy for undetectable postoperative PSA in patients at high risk of failure as judged on pathology, results are more encouraging. Recent data report bNED rates ≥70% at 5 years. Conclusions: Although results are far from satisfactory, salvage radiotherapy should be considered for every patient with an increased or detectable PSA after surgery. Adjuvant radiotherapy seems preferable to salvage radiotherapy for patients at high (>30%) risk of failure.

KW - Adjuvant radiotherapy

KW - Prostate carcinoma

KW - Prostatectomy

KW - Salvage radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0036880297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036880297&partnerID=8YFLogxK

M3 - Article

C2 - 12597135

AN - SCOPUS:0036880297

VL - 88

SP - 445

EP - 452

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 6

ER -